What this study is
This Phase 1b/2a study will primarily investigate the safety and tolerability of EYC-0305 delivered by intravitreal (IVT) injection every 24 weeks in patients with neovascular (wet) age-related macular degeneration (AMD). The pharmacokinetics (PK) and immunogenicity of EYC-0305, and the effect on disease activity and vision will also be evaluated.
What's being tested
- EYC-0305
Intervention · BIOLOGICAL
Extended-delivery anti-VEGF
Study details
- Official title
- Open-Label, Multiple Ascending Dose Phase 1b/2a Study of the Safety and Tolerability of Intravitreal (IVT) EYC-0305 in Patients With Neovascular Age-Related Macular Degeneration
- Sponsor
- Eyconis INC.
- Conditions
- Neovascular (Wet) Age-Related Macular Degeneration
- Enrolling
- 30 people
- Starts
- 2026-05-19
- Est. completion
- 2028-05
- Design
- Open-label, non-randomized, sequential groups, Phase 1, Phase 2
- Record
- View on ClinicalTrials.gov ↗
Who can join
Age 50 Years and overSex ALLHealthy volunteers Not acceptedYou may qualify if
- Men or women 50 years and older with neovascular (wet) AMD meeting all study-specified eligibility criteria
- Willing and able to comply with clinic visits and study-related procedures
- Provide signed informed consent
You can't join if
- Known hypersensitivity or known allergy that would preclude study drug administration
- Inability to obtain ophthalmic imaging, eg, due to media opacity, inadequate pupillary dilation, allergy to fluorescein dye or lack of venous access
- Uncontrolled diabetes mellitus
- History of cerebrovascular accident (CVA) or myocardial infarction within 180 days of the Day 1 visit
- Renal failure, dialysis, or history of renal transplant
- Concurrent psychiatric or medical condition that in the opinion of the Investigator will interfere with study participation or completion
- Pregnant or breastfeeding women
Sign in and we'll check these against your records.Full criteria on ClinicalTrials.gov ↗
Loading treatment details…
Study locations (7)
7 openBeverly Hills, CA
Beverly Hills, California, United States
RecruitingModesto, CA
Modesto, California, United States
RecruitingWake Forest, NC
Wake Forest, North Carolina, United States
RecruitingErie, PA
Erie, Pennsylvania, United States
RecruitingBellaire, TX
Bellaire, Texas, United States
RecruitingMcAllen, TX
McAllen, Texas, United States
RecruitingThe Woodlands, TX
The Woodlands, Texas, United States
Recruiting
Study team
Sponsor
Eyconis INC.
Study ID EYC-0305-2501
Frequently asked questions
The sponsor hasn't published answers to common questions for this trial.